ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells”

  ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People on Stem Cells”

 Dr. Lanza featured in “TOP 50 Global Stem Cell Influencers” along with James
                  Thomson and Nobel Laureate Shinya Yamanaka

Business Wire

MARLBOROUGH, Mass. -- March 12, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, announced today that chief scientific officer Robert
Lanza, M.D., is featured on the “TOP 50 Global Stem Cell Influencers” list
from Terrapinn’s life sciences division, TotalBiopharma (“World Stem Cells &
Regenerative Medicine Congress 2013”). The list features the most influential
people in the global stem cell and cell therapy field, including world
renowned academics, industry players, and governmental officials.

Dr. Lanza was among the top four on the list, alongside the University of
Wisconsin’s Dr. James Thomson, known as the first scientist to derive human
embryonic stem cells (in 1998) and for his work with induced pluripotent stem
(iPS) cells; and Kyoto University’s Dr. Shinya Yamanaka, co-winner of the 2012
Nobel Prize for Physiology or Medicine for his work with iPS cells, and a
winner of the inaugural $3 million Breakthrough Prize in Life Sciences earlier
this year.

Terrapinn, the global firm sponsoring the inaugural list, refers to it as
being similar to the “Forbes [Celebrity] 100, but for stem cells.” It is the
result of a global survey of the stem cell community, which yielded thousands
of votes. The 50 personalities were picked based on their career achievements
whether this was groundbreaking discovery and research, innovation, or
lifetime dedication. More information is available here.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2012. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292